Internal enhancement of DNA damage by a novel bispecific antibody‐drug conjugate‐like therapeutics via blockage of mTOR and PD‐L1 signal pathways in pancreatic cancer

Internal enhancement of DNA damage by a novel bispecific antibody‐drug conjugate‐like therapeutics via blockage of mTOR and PD‐L1 signal pathways in pancreatic cancer

Abstract Pancreatic ductal adenocarcinoma (PDAC) is a refractory malignant tumor with poor prognosis, limited chemotherapeutic efficacy, and only about 5% of 5‐year survival rate. We generated a dual‐targeting ligand‐based lidamycin (DTLL) to investigate its efficacy against pancreatic cancer after...

Full description

Bibliographic Details
Main Authors: Rui Cao, Wenping Song, Cheng Ye, Xiujun Liu, Liang Li, Yi Li, Hongjuan Yao, Xiaofei Zhou, Rongguang Shao
Format: Article
Language:English
Published: Wiley 2019-02-01
Series:Cancer Medicine
Subjects:
ADC‐like therapeutic agent
bispecificity
EGFR
HER2
pancreatic ductal adenocarcinoma
Online Access:https://doi.org/10.1002/cam4.1974

Internet

https://doi.org/10.1002/cam4.1974

Similar Items